Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

More time needed for US ICD (implantable cardioverter defibrillator) implantee registry:

This article was originally published in Clinica

Executive Summary

The US Heart Rhythm Society and the American College of Cardiology have asked Medicare officials to grant a period of grace before they require that all beneficiaries receiving an implantable cardioverter defibrillator be enrolled in a national registry. The medical groups said there is simply not enough time to establish the registry by the January 1 deadline set by the Centers for Medicare & Medicaid Services (CMS). A variety of details must be worked out first, including finding a source of funding and setting up a registry infrastructure, the groups said. The HRS is leading a working group that CMS has asked to address such issues. The group should advise CMS on a reasonable time for setting up the registry, the letter said.

You may also be interested in...



Study Says FDA Waited Too Long To Ban Pelvic Mesh For POP Repairs

Roughly 18.5% of patients who received reinterventions to fix mesh implants for pelvic organ prolapse (POP) repair experienced complications they will likely endure for the rest of their lives, and they also face a 2.5% higher rate of further surgeries than non-mesh patients, says a recent 54,194-woman study detailed in Obstetrics & Gynecology. The study authors lay out a case that the US FDA should have forced removal of mesh from the market sooner.

Execs On The Move: New R&D Chief Promotion At HAL Allergy; Two C-Level Appointments At Starkey

HAL Allergy Group, developer of products for allergy diagnostics and allergen immunotherapy, promoted its principal scientist to chief R&D officer; Starkey Hearing Technologies brought on new health and business development execs to expand its global footprint; and more.

Interview: Novartis's Big Hopes For Beovu

After a strong start in the US, Novartis is now ready to take on Bayer's wet age-related macular degeneration blockbuster Eylea in Europe.

Topics

UsernamePublicRestriction

Register

MT060142

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel